MG-132

Catalog No.S2619

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Cited by 45 publications:

9 customer reviews :

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cellsNH74fppHfW6ldHnvckBCe3OjeR?=MWKyOUDPxE1?M4m3TmROW09?MYXJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4yKM7:TR?=M{DXRlI1Pjl5NEm2
HL-60NV[1WGdnS3m2b4TvfIlkKEG|c3H5M3fCd|QxKM7:TR?=NXHuPYRHPDhiaB?=M4P0XGROW09?M3zRVGlEPTB:MUCg{txOMViyOFY6PzR7Nh?=
SMMC-7721M2jVfmN6fG:2b4jpZ{BCe3OjeR?=NWnhfVV5PDBizszNNHLkVlY1QCCqMlrrSG1UVw>?M3LzbmlEPTB;Nz6xJO69VQ>?M2jYUFI1Pjl5NEm2
A-549MkDuR5l1d3SxeHnjJGF{e2G7M2jSNlQxKM7:TR?=M{\SWVQ5KGh?MojNSG1UVw>?M3;l[WlEPTB:MUCg{txOM1;LTFI1Pjl5NEm2
MCF-7M4LuW2N6fG:2b4jpZ{BCe3OjeR?=NEPOWZM1OCEQvF2=NUT6[3pSPDhiaB?=NXnBRY1CTE2VTx?=NEXnbZZKSzVyPUeuN{DPxE1?MlW3NlQ3QTd2OU[=
SW-480NVzOVnR3S3m2b4TvfIlkKEG|c3H5MlzOOFAh|ryPMWK0PEBpMn\nSG1UVw>?NGLre3NKSzVyPUSg{txOMnvtNlQ3QTd2OU[=
NCI-H929NFXONFhEgXSxdH;4bYMhSXO|YYm=MXGxJO69VQ>?M{W5TlczKGh?M1L0dmROW09?MX;JR|UxRTBwMUeg{txONIO0NY8zPDZ{NUC4PC=>
293TMknvR5l1d3SxeHnjJGF{e2G7MnzPNVAh|ryPM{HYd|czKGh?MUDEUXNQNULLPXVPUUN3MEyyJO69VQ>?MUGyOFYzPTB6OB?=
293TNEXhXI9HfW6ldHnvckBCe3OjeR?=NV;6eHRuOTBizszNM{Pi[lI1KGh?NYfDTJhJTE2VTx?=MXvNc4RmemG2ZXz5JIlv\HWlZYOgbIVifC2|aH;jb{AhM3LLdFI1PjJ3MEi4
HeLaNFH0TFNMcW6jc3WgRZN{[Xl?MXGxNEDPxE1?NVexZnB1OSCqNWHEOYU6TE2VTx?=NGHjbYdKdmS3Y3XzJHBCWlBiY3zlZZZi\2ViYomgbY5pcWKrdHnu[{Bxem:|ZXHzc41mKGGldHn2bZR6NIXS[VEzPDN{MUizNy=>
MDA-MB-231M2XuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3Ln[lEh|ryPMkHsO|IhcA>?MVTEUXNQNEXKUHhKSzVyPUCuNVgh|ryPNFvKfnMzPDF3M{KwOi=>
MCF-7MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnzSnV[OSEQvF2=MYi3NkBpMn60SG1UVw>?M1TJT2lEPTB;MD6xN{DPxE1?Mnj6NlQyPTN{ME[=
MCF10ANHLjSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;J[I8yKM7:TR?=Mlz4O|IhcA>?NWH2[JB6TE2VTx?=M1jVSWlEPTB;MD6yPUDPxE1?MnjGNlQyPTN{ME[=
HEK-293MmT2T4lv[XOnIFHzd4F6MXiyJIFv\CB{MDFOwG0>NUC0UodZOiCqMnTvSG1UVw>?NIDoZ4RKdmirYnn0d{BEcFRvTDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhQSCwTTC=M4DiZVI{PTRyN{mw
Calu6MV3GeY5kfGmxbjDBd5NigQ>?NYP3N5R3OTBizszNNEPFOm0yQCCqNV\WbWRYTE2VTx?=MYnTbYdvcW[rY3HueIx6KGGlY4XteYxifGW|IH\yZZRigGmwIIDy[YN2enOxch?=NWDGenlYOjN3ME[0PFY>
IFN-gamma-induced RAW264.7M{DvbmZ2dmO2aX;uJGF{e2G7NEfadVdFVVORNUmyR5hHUW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>?M3vHXFIzOjd5Mke3
IPC227FMn7KR5l1d3SxeHnjJGF{e2G7M1PvTVEh|ryPNXPLPHlbPDhiaB?=MULEUXNQMmTwTWM2OD1yLkC3O{DPxE1?M3G3NFIyQTJ2NUK4
Hepa-1c1c7MmrkSpVv[3Srb36gRZN{[Xl?MXGyOUDPxE1?Ml3SOkBpMUTEUXNQNHTLTXBKdmO{ZXHz[ZMhVnKoMjDwdo91\WmwIHzleoVtNWPNZVBrOjB|OUK1OFQ>
COS-7MnjSR5l1d3SxeHnjJGF{e2G7MUCxNEDPxE1?NYnGSYlwTE2VTx?=MYfJR|UxRDFyIN88US=>M3nORVE5ODh6MEm3
HuH-7MlHWR5l1d3SxeHnjJGF{e2G7NXrobIF5OTBizszNMVvEUXNQNHriPJRKSzVyPEGwJO69VQ>?NVn4WJlDOThyOEiwPVc>
OCI-Ly3MlThSpVv[3Srb36gRZN{[Xl?NEPzV5oyOCEQvF5CpC=>MkXDOEBpMn\uSG1UVw>?MWfJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>?M{\xb|E5ODJ2MUGz
A2780 cDDPNEjseYhCeG:ydH;zbZMhSXO|YYm=NG\j[5gzPCCqNYrr[nhzTE2VTx?=MWTJcoR2[2W|IHHwc5B1d3OrczDifUBqdmirYnn0bY5oKFCWRV6g[IVoemGmYYTpc44>Ml\rNVc3QDRyMUi=
LPS-stimulated RAW264.7 cellsMo\hSpVv[3Srb36gRZN{[Xl?Mnf2SG1UVw>?NFnmW2VKdmirYnn0d{BPTi2tYYDwZWIhTE6DIHLpcoRqdmd?MVSxO|QxPzJ5Nx?=
PC12MkfFSpVv[3Srb36gRZN{[Xl?MX6xNFAh|ryPwrC=M3HoelI1KGh?MYrEUXNQNF;jZWRKdmirYnn0d{A3NU:KRFGtJIFv\CCKMl:yMYlv\HWlZXSgZ5l1d3SxeHnjbZR6Mn\4NVcyPTh2NUS=
PC3M2foUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXaZ4IzOCEQvF2=MofYOFghcA>?MVHEUXNQMkDwTWM2OD1yLk[g{txONXXGTIFbOTZ4OE[1N|c>
LP-1M1W0W2Fxd3C2b4Ppd{BCe3OjeR?=NEC5TVI{ODBibl2=NFP4SIkzPCCqMkD6SG1UVw>?MXXJcoR2[2W|IHHwc5B1d3OrczDifUBqdmO{ZXHzbY5oKGOuZXH2[YQhWEGUUDDs[ZZmdCCjbnSgdoVlfWOrbnegUYNtNTFicILveIVqdiCuZY\lcC=>M3;NW|E2QTV6NUi5
ES6Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXX3fXBDUUN3ME2wMlAyOzB4IN88US=>MX\TRW5ITVJ?
A101DM2\KXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmmzTWM2OD1yLkCzNlc6KM7:TR?=NEXpUGNUSU6JRWK=
OCUB-MM2LWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTBwMEO3N|ch|ryPNVjaW|NlW0GQR1XS
LB2518-MELMkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPDU3V6UUN3ME2wMlA{PzZizszNMlOyV2FPT0WU
SH-4MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{S1[2lEPTB;MD6wOFMyKM7:TR?=NYn2OFV3W0GQR1XS
KNS-42MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHxTWM2OD1yLkC0OFQyKM7:TR?=NIHINHVUSU6JRWK=
DSH1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2H6T2lEPTB;MD6wOVI5QSEQvF2=NVfBeWZTW0GQR1XS
NTERA-S-cl-D1NVfhbZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYX0[25rUUN3ME2wMlA2Pzd{IN88US=>M13h[XNCVkeHUh?=
D-542MGMnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHy3cW1KSzVyPUCuNFU6PTdizszNMkPFV2FPT0WU
KS-1Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTBwME[0OVgh|ryPMl;jV2FPT0WU
BL-41NU\Lbo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTBwME[5OFch|ryPNEP4XoVUSU6JRWK=
LXF-289NXqwUlBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPLeWdKSzVyPUCuNFcxPjZizszNNWn6UlZ6W0GQR1XS
D-247MGNHf3bnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rmeGlEPTB;MD6wO|IxQSEQvF2=MlLMV2FPT0WU
MMAC-SFNUXGN2tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3S5XGlEPTB;MD6wO|I3QCEQvF2=M4OzPHNCVkeHUh?=
CP66-MELNX7ve4VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTBwMEe1JO69VQ>?Ml;PV2FPT0WU
LB771-HNCM3;NVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTBwMEiwN|Yh|ryPNFjYTJZUSU6JRWK=
no-10NWHISVV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;zcGlEPTB;MD6wPFkxQSEQvF2=NWDYZXVmW0GQR1XS
A388NYe1eIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonBTWM2OD1yLkC5NFY2KM7:TR?=MVXTRW5ITVJ?
OPM-2NYjzWZNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3hW4dKSzVyPUCuNVA1PzRizszNNHHaZmFUSU6JRWK=
OVCAR-4M3zPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDI[W0yUUN3ME2wMlExQTN6IN88US=>Mn34V2FPT0WU
HOP-62MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fXfGlEPTB;MD6xNFk1QSEQvF2=M3fnWHNCVkeHUh?=
ML-2NIXIcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLr[4pKSzVyPUCuNVE5ODZizszNMoHiV2FPT0WU
UACC-257M4i2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX2yPZZSUUN3ME2wMlEyQTJ5IN88US=>NUDNPYJjW0GQR1XS
NEC8MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTBwMUG5PVUh|ryPNFHYOXBUSU6JRWK=
ONS-76NEnS[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTa[2RPUUN3ME2wMlEzQTN3IN88US=>M1rIRXNCVkeHUh?=
KE-37M2rBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTMeZhZUUN3ME2wMlE{Ojd6IN88US=>NV[wcphJW0GQR1XS
HT-144NEPocIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfSdlZKSzVyPUCuNVM5QTVizszNMn\3V2FPT0WU
LB2241-RCCMmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljyTWM2OD1yLkG0NlQ4KM7:TR?=M4[4VnNCVkeHUh?=
TE-5MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTWTWM2OD1yLkG0Nlc5KM7:TR?=NXf0b2lFW0GQR1XS
KINGS-1NFLIWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{KxU2lEPTB;MD6xOFc6KM7:TR?=MnnmV2FPT0WU
NCI-H69M1TNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\5SWlEPTB;MD6xOVE1OSEQvF2=M2XWT3NCVkeHUh?=
CAS-1NHy5Z4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7rRpV7UUN3ME2wMlE2PDh{IN88US=>MVPTRW5ITVJ?
D-263MGMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13admlEPTB;MD6xOlAxPiEQvF2=MYDTRW5ITVJ?
A253M1rzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;mUmlEPTB;MD6xOlEzQCEQvF2=NXi1[phKW0GQR1XS
PF-382MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFThd|lKSzVyPUCuNVY4ODZizszNNXfLeYM1W0GQR1XS
CESSMnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfGN29KSzVyPUCuNVcxPiEQvF2=Mn3pV2FPT0WU
MZ2-MELMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTFeJpTUUN3ME2wMlE4PTV7IN88US=>MnLSV2FPT0WU
HELM{nadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTtfpBEUUN3ME2wMlE5PTF5IN88US=>MVvTRW5ITVJ?
D-392MGNITaXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HBVWlEPTB;MD6xPVEyPSEQvF2=MVLTRW5ITVJ?
SK-LMS-1Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnnPWd5UUN3ME2wMlE6OzB|IN88US=>MmnXV2FPT0WU
GI-ME-NMl3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\GTWM2OD1yLkG5N|A3KM7:TR?=MWXTRW5ITVJ?
LB831-BLCNHTENYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33T[mlEPTB;MD6xPVM1KM7:TR?=MYnTRW5ITVJ?
DU-4475MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmT4TWM2OD1yLkG5OlU5KM7:TR?=NGTmeGlUSU6JRWK=
IST-SL1M2LrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWexTWNrUUN3ME2wMlIxODl2IN88US=>MVzTRW5ITVJ?
GAKNEnpd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTyeVBKUUN3ME2wMlIxPTN2IN88US=>MkflV2FPT0WU
EW-1M1XLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;IS4JoUUN3ME2wMlIyODR5IN88US=>NYrDTZcxW0GQR1XS
LAMA-84MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUOzbHdDUUN3ME2wMlIyQDVzIN88US=>MknJV2FPT0WU
SK-UT-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTBwMkKwOFkh|ryPMmL6V2FPT0WU
VA-ES-BJNYW1XlhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYe3fGllUUN3ME2wMlIzOjV5IN88US=>NXfn[4JJW0GQR1XS
ACNNIfTTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TJT2lEPTB;MD6yNlY{QCEQvF2=MXLTRW5ITVJ?
SK-PN-DWMlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrQdYdKSzVyPUCuNlMyQSEQvF2=MmiwV2FPT0WU
HD-MY-ZNHOzWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTBwMkOzNFMh|ryPNU\YRY55W0GQR1XS
LB373-MEL-DMnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljUTWM2OD1yLkK0NVk5KM7:TR?=M4jkR3NCVkeHUh?=
COLO-829M1Pj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTBwMkSyOVch|ryPNGPUfJZUSU6JRWK=
ES8MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjzbHVuUUN3ME2wMlI1PzZ|IN88US=>Mn3EV2FPT0WU
RXF393NFHXOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LGcWlEPTB;MD6yOVAyPSEQvF2=NWLQS3JpW0GQR1XS
TK10NF\x[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwMkW0N|Uh|ryPMoqyV2FPT0WU
LOUCYMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1z2VWlEPTB;MD6yOVQ2PiEQvF2=NH3hXVBUSU6JRWK=
MZ7-melM4XFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TRXGlEPTB;MD6yOlM4PCEQvF2=NFjiU2pUSU6JRWK=
CP67-MELMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTMTWM2OD1yLkK2O|Mh|ryPMknOV2FPT0WU
C2BBe1MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTBwMke5NFch|ryPNX\PWlN{W0GQR1XS
K052M13wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzSO5pKSzVyPUCuNlg6QSEQvF2=M3;DW3NCVkeHUh?=
MOLT-16M{jZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlz2TWM2OD1yLkK5OVI1KM7:TR?=NV\HO5dvW0GQR1XS
KNS-81-FDMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;NU2lEPTB;MD6zNFMzOyEQvF2=NIXn[pBUSU6JRWK=
CMKMm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\NTWM2OD1yLkOxNVIh|ryPNX64b415W0GQR1XS
LAN-6NIfBSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnjOIJxUUN3ME2wMlMyOyEQvF2=MkfDV2FPT0WU
KLEM4jod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPwe5dKSzVyPUCuN|E{ODZizszNMX3TRW5ITVJ?
NCCITM2mw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfYNHFKSzVyPUCuN|E4QDNizszNNIPTdZVUSU6JRWK=
HHMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoroTWM2OD1yLkOyPFk4KM7:TR?=NUOzU5J1W0GQR1XS
TE-8NHLEeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTBwM{SyO|kh|ryPMUfTRW5ITVJ?
GDM-1NIPNdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTBwM{WxNFQh|ryPMljvV2FPT0WU
NCI-H747MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LzTGlEPTB;MD6zO|ExOyEQvF2=MYrTRW5ITVJ?
NCI-H1092NFHhdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHu2SpVKSzVyPUCuN|g5PDRizszNM3TLcnNCVkeHUh?=
8-MG-BANXX1NXhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInV[ldKSzVyPUCuN|k5OzdizszNNU\UflZKW0GQR1XS
NB17MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGixU5NKSzVyPUCuOFI6PyEQvF2=NH;X[oNUSU6JRWK=
LC4-1M2PNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLKTWM2OD1yLkSzOlA4KM7:TR?=Mo\DV2FPT0WU
TE-1NYHBZ3ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1m5SGlEPTB;MD60OVEyQSEQvF2=M33ySnNCVkeHUh?=
KALS-1M3;YWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXr0[XVZUUN3ME2wMlQ3PTh2IN88US=>M1LxenNCVkeHUh?=
CCRF-CEMNH\VOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwNEe2O|Qh|ryPNFzDNJpUSU6JRWK=
OS-RC-2NIO5OY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIi4XY9KSzVyPUCuOFc6PzJizszNM2qycHNCVkeHUh?=
A704Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml:1TWM2OD1yLkS4OlkzKM7:TR?=MmjBV2FPT0WU
BB49-HNCMnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\KNGlEPTB;MD60PVA6PiEQvF2=NXnsT4RVW0GQR1XS
EVSA-TNV;EepN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LENmlEPTB;MD60PVkyOSEQvF2=NVrWbGlkW0GQR1XS
Mo-TNIDRVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTBwNUG3OlIh|ryPMnzBV2FPT0WU
MONO-MAC-6NVHxVWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTBwNUO2NVEh|ryPMYPTRW5ITVJ?
BB65-RCCMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLGNJZKSzVyPUCuOVY5OTFizszNNH3RWXRUSU6JRWK=
NCI-H1882MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rOdGlEPTB;MD61PVA{PiEQvF2=NH7SfFFUSU6JRWK=
TE-9M4qzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTBwNkGwN|Mh|ryPMlXTV2FPT0WU
NCI-H2126NIOyT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;uTWM2OD1yLk[yOlY6KM7:TR?=MUDTRW5ITVJ?
SF268M2XnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPnZYl{UUN3ME2wMlY2PjRzIN88US=>NUfwWopbW0GQR1XS
SW872M3rWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHOXFhKSzVyPUCuOlU4OjlizszNMmnSV2FPT0WU
LS-513MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYftV5diUUN3ME2wMlY3PzVzIN88US=>NFqzU2tUSU6JRWK=
NCI-H1355NWXGbHV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYL3RopiUUN3ME2wMlY5PjF7IN88US=>MV3TRW5ITVJ?
BL-70MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljxTWM2OD1yLk[5N|g5KM7:TR?=Ml\KV2FPT0WU
NCI-SNU-5NW\pT5lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTBwNkm1OFUh|ryPMoTrV2FPT0WU
SNU-C2BMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW[5WZVwUUN3ME2wMlcxPzN7IN88US=>M{nCUnNCVkeHUh?=
GB-1NXn2[Gt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTET3pzUUN3ME2wMlczOTJ2IN88US=>NHW3NJVUSU6JRWK=
CTB-1NInhPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rmXmlEPTB;MD63O|k2PSEQvF2=MUjTRW5ITVJ?
BeckerNHnDOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfEU3pKSzVyPUCuO|k3OjFizszNNH;he5JUSU6JRWK=
KM12MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwOEW0OlYh|ryPNI\ZcW5USU6JRWK=
ES7NXrOVXNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXRXo52UUN3ME2wMlg6PjVizszNNHK0bpNUSU6JRWK=
COLO-684NH[yd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LyRmlEPTB;MD65NFY2QCEQvF2=MXnTRW5ITVJ?
HCC2998NV3BVllVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\0VmlEPTB;MD65N|g2PCEQvF2=NIHqSWxUSU6JRWK=
TE-10Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTBwOU[0N{DPxE1?NWDlS3FMW0GQR1XS
SF126NXrWfHR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHv0[3hKSzVyPUCuPVg6PzFizszNNXjFTIFjW0GQR1XS
EKVXMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTFwMEO0OFIh|ryPM4\KcnNCVkeHUh?=
KARPAS-45M33xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TU[2lEPTB;MT6wOFAyPiEQvF2=NUDi[JZ6W0GQR1XS
KGNMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHncGlKSzVyPUGuNFUxPDVizszNMnyxV2FPT0WU
ES1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkntTWM2OD1zLkC3PVIyKM7:TR?=NGPKPGxUSU6JRWK=
L-540M4nXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnv1TWM2OD1zLkGxPFM6KM7:TR?=MWfTRW5ITVJ?
KURAMOCHINHnPZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTFwMUKzO|Qh|ryPMkLwV2FPT0WU
LU-65NYfhc4tCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFwMUK3OVMh|ryPMmiwV2FPT0WU
MFH-inoMnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrJTWM2OD1zLkG3OVAyKM7:TR?=NFLSe2ZUSU6JRWK=
NCI-H23NWDReY1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3DTWM2OD1zLkKwOFEh|ryPNGnaNFdUSU6JRWK=
IA-LMNYXxVIJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULnR3F6UUN3ME2xMlI1OTF4IN88US=>M3rqXHNCVkeHUh?=
PSN1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTFwMkewNVYh|ryPNV;BSWhHW0GQR1XS
NCI-H719MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXITHVKSzVyPUGuNlc1OTFizszNM1XxRnNCVkeHUh?=
SW684MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTFwMki2OVkh|ryPNFP1cGZUSU6JRWK=
HCE-4NWPoS4FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTFwM{CyNlEh|ryPNIDlWG5USU6JRWK=
EW-16MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{K3NmlEPTB;MT6zNVM1PyEQvF2=MkPXV2FPT0WU
NCI-H128MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\BSXpNUUN3ME2xMlM2QDF2IN88US=>NXy4WldoW0GQR1XS
HC-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG[zOJRKSzVyPUGuN|gyPyEQvF2=MWPTRW5ITVJ?
IST-MES1NXvNNm5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFwNECyNFgh|ryPMVrTRW5ITVJ?
RajiM2H6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfXTWM2OD1zLkSxPFUh|ryPMUPTRW5ITVJ?
DMS-114M4q0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPTO4dKSzVyPUGuOFQ2OzlizszNM{jvfnNCVkeHUh?=
GI-1NULhV|ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHriUIZKSzVyPUGuOFcyOzFizszNNGrhWJVUSU6JRWK=
NCI-H2081NYDUU4dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPLTJFDUUN3ME2xMlU2OTl4IN88US=>MmrSV2FPT0WU
LC-1FNImxfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTFwNUWxPVgh|ryPMoS1V2FPT0WU
NCI-H2227NHvaUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDxXoVKSzVyPUGuOlE2PjFizszNMn3hV2FPT0WU
D-502MGNHHNNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTFwNkeyNVEh|ryPMVjTRW5ITVJ?
NCI-H2141MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTFwNkezNVch|ryPNEPPS4lUSU6JRWK=
LS-411NNETXWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTofFBKSzVyPUGuOlk5ODdizszNNIjhUpdUSU6JRWK=
SU-DHL-1NHLEdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\yR2lEPTB;MT63NVI5OSEQvF2=NG\KSXNUSU6JRWK=
BB30-HNCMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnNTWM2OD1zLkeyOlg2KM7:TR?=MV;TRW5ITVJ?
TE-15M3f5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXic|RKSzVyPUGuPVI{PzNizszNNGPmd|VUSU6JRWK=
JVM-3NX7DOI9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFwOUO5NFQh|ryPM4TqenNCVkeHUh?=
IST-SL2NVHBZopHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTJwMEGyOVIh|ryPNVTJRYtCW0GQR1XS
EW-18M1PkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3KyXWlEPTB;Mj6wNlM{PyEQvF2=MUfTRW5ITVJ?
DJM-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\wTWM2OD1{LkCyOVUzKM7:TR?=M2XkW3NCVkeHUh?=
no-11NHHENWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljSTWM2OD1{LkCzNVA1KM7:TR?=MmPNV2FPT0WU
QIMR-WILNInPSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{D1V2lEPTB;Mj6xOlc3OiEQvF2=M3q2VHNCVkeHUh?=
MC-CARNETYNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWq5UWJPUUN3ME2yMlIzQTVizszNM3PNSnNCVkeHUh?=
KM-H2NIO5fFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\vTpFKSzVyPUKuNlkxPDNizszNNH\FeVNUSU6JRWK=
ECC12Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4m5OWlEPTB;Mj6zO|k1KM7:TR?=NF;JO|ZUSU6JRWK=
HCE-TNX3CVpc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjYTWM2OD1{LkS0PFg{KM7:TR?=NITGcotUSU6JRWK=
MFM-223MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLuVJZHUUN3ME2yMlUxQDdzIN88US=>MnLuV2FPT0WU
SW982M1\0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTJwNUG0PEDPxE1?MmfKV2FPT0WU
KG-1M37HUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzHU2Q{UUN3ME2yMlg5PzlzIN88US=>M2Pk[nNCVkeHUh?=
ES4NHjGU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlGzTWM2OD1|LkC2NVEyKM7:TR?=MXLTRW5ITVJ?
SCC-3NGLzTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlriTWM2OD1|LkGwPFQ5KM7:TR?=MnK3V2FPT0WU
RH-1NH\qcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33qOGlEPTB;Mz6zPFc1QCEQvF2=MXPTRW5ITVJ?
NCI-H748M3y2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7rcIpKSzVyPUOuOFQzPjZizszNMY\TRW5ITVJ?
HCC2218MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWj0NIQzUUN3ME2zMlQ3QTN5IN88US=>NXT3ZlNRW0GQR1XS
MEG-01MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2W2fmlEPTB;Mz61PVY5KM7:TR?=M3PKXnNCVkeHUh?=
NB12NXHZWHk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIiwcWZKSzVyPUOuOVk5QDhizszNMlnJV2FPT0WU
SNB75M1Tjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HuZWlEPTB;Mz62NFExOyEQvF2=MYLTRW5ITVJ?
KMS-12-PENITuO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXrXnBKSzVyPUOuOlc4OjNizszNNXfu[nBjW0GQR1XS
SKM-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1e2e2lEPTB;Mz63NVM4PiEQvF2=MoWwV2FPT0WU
COLO-320-HSRM1vwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXZTWM2OD1|Lke1OlM1KM7:TR?=NYnpWnM5W0GQR1XS
NKM-1M3HvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;TdGlEPTB;Mz63O|M4QCEQvF2=NYq5WVR[W0GQR1XS
TE-6NGfaPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoW5TWM2OD1|Lkm0OVYyKM7:TR?=M3r6RXNCVkeHUh?=
D-336MGNES3cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\YTWM2OD12LkCxNVY3KM7:TR?=NYiwbmpQW0GQR1XS
NCI-H1650NYPt[ldkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfkeVZvUUN3ME20MlE2Pzl5IN88US=>NIraVFNUSU6JRWK=
ES3Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnhWHQ2UUN3ME20MlMzQDJ2IN88US=>MXPTRW5ITVJ?
YTNIHWbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIWxWm9KSzVyPUSuN|U1OjRizszNNFLIOmNUSU6JRWK=
ES5M3PYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTiXoFKSzVyPUSuOFAzPTVizszNM{\HdXNCVkeHUh?=
LB647-SCLCM4XkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLudZRzUUN3ME20MlU3OzB6IN88US=>MnfRV2FPT0WU
HAL-01NXfhbGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vPOWlEPTB;ND61O|A{PCEQvF2=NH7HRmlUSU6JRWK=
LP-1MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDDdFhKSzVyPUSuO|I{PzFizszNM13mTHNCVkeHUh?=
BC-1NWi5NIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTITWM2OD13LkCwOFQ4KM7:TR?=NGjt[lFUSU6JRWK=
EB-3M3znVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDsWVNKSzVyPUWuNFMxPDFizszNNHzxO2RUSU6JRWK=
GT3TKBM4q5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfBN5VFUUN3ME21MlE4PjZ{IN88US=>M1rBe3NCVkeHUh?=
NCI-H209MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFn4e|VKSzVyPUWuNVk{PTJizszNMWDTRW5ITVJ?
BT-474M4TRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zIUGlEPTB;NT6yN|ExOiEQvF2=NXXsNYx2W0GQR1XS
RKOM4HGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHO1WmtKSzVyPUWuNlM1OjJizszNM1LWfnNCVkeHUh?=
SIMANHHGc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\aTWM2OD13LkOwO|Y2KM7:TR?=NVT0dFdsW0GQR1XS
RLM{fKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUKyXHRjUUN3ME21MlM4PTRzIN88US=>NHexcYFUSU6JRWK=
GCIYNUHZfIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LrSWlEPTB;NT60O|I{PiEQvF2=M3jsSnNCVkeHUh?=
Calu-6NXWxSFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LRR2lEPTB;NT62NlIh|ryPMk[3V2FPT0WU
ALL-POM4i5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPhTWM2OD13Lk[zO|k2KM7:TR?=MWjTRW5ITVJ?
ARH-77NVPocnQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoT5TWM2OD13Lk[3NFg4KM7:TR?=MV3TRW5ITVJ?
A4-FukNIPaO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUSxZZJLUUN3ME22MlA5OTF6IN88US=>M3rjfnNCVkeHUh?=
NCI-H1581M{fDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XSPGlEPTB;Nj6yN|g1QSEQvF2=M2W2NXNCVkeHUh?=
HUTU-80NVS4e3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTZwM{[4PVch|ryPMWPTRW5ITVJ?
TGWMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3MTWM2OD14LkS1OVk{KM7:TR?=NXixcHNxW0GQR1XS
SK-N-FIMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXHe3FKSzVyPU[uOFU5PTRizszNMVvTRW5ITVJ?
U-266M2K5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnMTWM2OD14LkWxPVI3KM7:TR?=M1vrNXNCVkeHUh?=
EM-2MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37IdmlEPTB;Nj62O|A6QSEQvF2=MV;TRW5ITVJ?
NMC-G1NH;FTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vueGlEPTB;Nj63NVg6PSEQvF2=MUHTRW5ITVJ?
KASUMI-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTZwOES3PFch|ryPNGe4[IRUSU6JRWK=
NALM-6M1\ORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHuzO2xKSzVyPU[uPFY4PTRizszNM13C[XNCVkeHUh?=
OCI-AML2NIewepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4iwTmlEPTB;Nz6wNFMzPiEQvF2=M1nXVnNCVkeHUh?=
SHP-77MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nPfGlEPTB;Nz6yNlQ{KM7:TR?=Moe1V2FPT0WU
NOMO-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWH5cnk{UUN3ME23MlI1OjV2IN88US=>NGjXN5NUSU6JRWK=
SK-N-DZM3L3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTdwN{GwPFkh|ryPM3PhdHNCVkeHUh?=
LB1047-RCCMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PkTmlEPTB;Nz63NlI{OSEQvF2=MonnV2FPT0WU
MZ1-PCNWnjWIM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13yS2lEPTB;Nz64OlU2QCEQvF2=M{HlW3NCVkeHUh?=
NB10MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPBTWM2OD15Lkm5OVU3KM7:TR?=MmPUV2FPT0WU
RL95-2MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUiwcY5HUUN3ME24MlExQDR{IN88US=>M2DUbXNCVkeHUh?=
OMC-1Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4T3eGlEPTB;OD61NlE6OSEQvF2=M3j3S3NCVkeHUh?=
D-283MEDM2PEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DPdGlEPTB;OD65NVcyQSEQvF2=MljlV2FPT0WU
MC116MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm[0TWM2OD16Lkm3PVQh|ryPNITZU|NUSU6JRWK=
SJSA-1M{KyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nIXGlEPTB;OT6wPVA6OSEQvF2=NXLoTIt[W0GQR1XS
JiyoyeP-2003NVTZVmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTlwMkmzNVch|ryPMWfTRW5ITVJ?
IST-MEL1MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LrW2lEPTB;OT63OFE6QCEQvF2=NWLRWXRTW0GQR1XS
CTV-1M{Kw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHSVllKSzVyPUGwMlA6PzlizszNNFridmdUSU6JRWK=
NH-12MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTFyLkK0N|Mh|ryPMX7TRW5ITVJ?
CA46M1\RSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTFyLkO2NUDPxE1?NGHTW|RUSU6JRWK=
NCI-SNU-1NIf1NINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13KRmlEPTB;MUCuOFk3QSEQvF2=MWfTRW5ITVJ?
SCLC-21HNX3oW|RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zsbWlEPTB;MUCuOlU6PiEQvF2=MlvFV2FPT0WU
EC-GI-10NYT5VIJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fOb2lEPTB;MUCuO|A{OSEQvF2=NYTxV3k2W0GQR1XS
SRM1Hxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDGdZVKSzVyPUGxMlAyQDVizszNMVfTRW5ITVJ?
NCI-H1648NYfFWWxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFSzb5dKSzVyPUGxMlA6PjVizszNMnvXV2FPT0WU
TGBC1TKBNGW2fYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLV[ZVKSzVyPUGxMlQyODJizszNMV\TRW5ITVJ?
EW-11M4X3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPaZ49KSzVyPUGxMlUyQDZizszNM1\RU3NCVkeHUh?=
SK-MM-2Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfoTWM2OD1zMT64NFYyKM7:TR?=Mn;QV2FPT0WU
NCI-H524MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTFzLkm4NlIh|ryPNIHwRVJUSU6JRWK=
NOS-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3KzOWlEPTB;MUKuNFM1PSEQvF2=NV\6XHVbW0GQR1XS
AM-38M1fDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnz4TWM2OD1zMj61OlM{KM7:TR?=MmLLV2FPT0WU
A498NI\zVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTF{LkewOlkh|ryPMmXNV2FPT0WU
KARPAS-422MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIC5Xm5KSzVyPUGyMlc1QTZizszNNFntSpFUSU6JRWK=
LU-139NU\XemwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnu3TWM2OD1zMj65NFI3KM7:TR?=M4HhVHNCVkeHUh?=
COR-L88NUKycohPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPSNGsxUUN3ME2xNk46Ozh{IN88US=>M2PLOXNCVkeHUh?=
K5M4GweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXr[HdKSzVyPUGyMlk1PjJizszNNV3hUHZSW0GQR1XS
NB13NGrjN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDWeXpWUUN3ME2xNk46Pzh|IN88US=>MVLTRW5ITVJ?
MRK-nu-1M4TUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;qVWVwUUN3ME2xN{4yQTVizszNMWPTRW5ITVJ?
MHH-NB-11NFfaNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTF|LkK5NFIh|ryPM3\ocHNCVkeHUh?=
KU812NVnhZoxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;HfnJ2UUN3ME2xN{43OTJ2IN88US=>M3XtfHNCVkeHUh?=
TE-12MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTF|Lk[5PVQh|ryPMlK5V2FPT0WU
NCI-N87MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TBUWlEPTB;MUOuO|M3KM7:TR?=NI\RUppUSU6JRWK=
EB2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDBTWM2OD1zMz64OVA2KM7:TR?=MXrTRW5ITVJ?
DBNYXTfXl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTF|Lkm4PFUh|ryPMkiwV2FPT0WU
697Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvLW|ZKSzVyPUG0MlQ2OTFizszNNH33THFUSU6JRWK=
MSTO-211HM1PjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVf6[opkUUN3ME2xOE44PDR6IN88US=>Mni2V2FPT0WU
JVM-2MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTF2Lke3N|Uh|ryPMXPTRW5ITVJ?
COLO-824MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTF2Lke5PVQh|ryPNV3UV2gzW0GQR1XS
BC-3MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXNTWM2OD1zNT6zPVgh|ryPMn[0V2FPT0WU
BOKUMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXTTWM2OD1zNT65OlA5KM7:TR?=NIHXNY5USU6JRWK=
GOTOMmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTF4Lkm2NVch|ryPMUnTRW5ITVJ?
HCC2157M2TNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTF5LkS3OVUh|ryPNUSyUGhEW0GQR1XS
LS-1034M2roXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfvdnhKSzVyPUG3MlY5OThizszNMnjwV2FPT0WU
CAL-148NH7RfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYm2XnB[UUN3ME2xO{46Pzl4IN88US=>NYrkbVd3W0GQR1XS
MOLT-4NHHiNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTF6LkiyNFgh|ryPNVvic21JW0GQR1XS
DaudiMn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTF6LkmyN|Eh|ryPM4K1cnNCVkeHUh?=
J-RT3-T3-5M{n4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTF7LkSwOlYh|ryPNWjCV4l4W0GQR1XS
KMOE-2MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PpPWlEPTB;MUmuOlQ5OiEQvF2=M1S3bXNCVkeHUh?=
HL-60MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3GTWM2OD1{MD6xPVY2KM7:TR?=NXq2VWQ1W0GQR1XS
P31-FUJM{CyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XmXGlEPTB;MkCuOFc2OyEQvF2=MXXTRW5ITVJ?
IM-9NXvVc2luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTJyLk[yNlQh|ryPMn7HV2FPT0WU
HDLM-2NXHPWppsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlG3TWM2OD1{MD64PFIyKM7:TR?=NYXDRnI{W0GQR1XS
NCI-H1304MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rhNWlEPTB;MkGuNFMyOSEQvF2=MkLwV2FPT0WU
NCI-H345MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfQXYYxUUN3ME2yNU4xPjR|IN88US=>NIXyOVRUSU6JRWK=
RPMI-6666MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vTbGlEPTB;MkGuN|YxOiEQvF2=M3fM[XNCVkeHUh?=
GR-STM2W0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUG4[FIxUUN3ME2yNU41OTdizszNM4\XO3NCVkeHUh?=
CHP-126NF23U3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLlTWM2OD1{MT62NVgyKM7:TR?=NH;0SXFUSU6JRWK=
EHEBMl\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUToWo9GUUN3ME2yNU43PzNzIN88US=>NWW0ZpJxW0GQR1XS
CPC-NM2LrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fa[GlEPTB;MkSuNFIxOSEQvF2=M1LhfnNCVkeHUh?=
NB1NWLSPJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEKzTlBKSzVyPUK0MlY6OzlizszNNYfz[IRMW0GQR1XS
LS-123MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjpSodKSzVyPUK0MlkxOTJizszNMlTIV2FPT0WU
ST486MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTGNmFRUUN3ME2yOU4yOTF|IN88US=>NF7lXopUSU6JRWK=
NCI-H1963NH:y[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITzVHNKSzVyPUK2MlA3OjNizszNNFK0VpVUSU6JRWK=
U-87-MGNF;k[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1y3PWlEPTB;Mk[uO|Y1PCEQvF2=MVfTRW5ITVJ?
COR-L279NFfyZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTJ4Lke5NlIh|ryPNV\MZ2tOW0GQR1XS
LU-165M1nTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTJ6LkC4OlEh|ryPNH;k[oZUSU6JRWK=
COLO-800NEXVWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2K5T2lEPTB;MkiuNlk2PiEQvF2=NYTXeJd7W0GQR1XS
ETK-1NEDPb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\CfJFKSzVyPUK4MlM1PDZizszNNGH3T3dUSU6JRWK=
LNCaP-Clone-FGCMnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXroNGJ6UUN3ME2yPU46OjhzIN88US=>MXnTRW5ITVJ?
SIG-M5Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVO5e4J4UUN3ME2zNE44QTV{IN88US=>NEPCbJVUSU6JRWK=
NB6MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3NTZRlUUN3ME2zNE46PTB|IN88US=>NVP1N5pKW0GQR1XS
NCI-H2107NEjlSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTNzLkKzN|gh|ryPNHTDbolUSU6JRWK=
SNU-C1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jJ[mlEPTB;M{GuN|EzPiEQvF2=M4HVZnNCVkeHUh?=
JARM{W0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2ntOWlEPTB;M{GuN|c6QSEQvF2=MWjTRW5ITVJ?
L-363MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLTTWM2OD1|Mj6yNVQ1KM7:TR?=MlXQV2FPT0WU
EW-24NFv0cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPwTWM2OD1|Mj6zOFc1KM7:TR?=MYTTRW5ITVJ?
NB69NWnrZocxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2e2[WlEPTB;M{OuOlQ2PCEQvF2=MmK1V2FPT0WU
EW-13NF3ybWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7STWM2OD1|Mz64PVY6KM7:TR?=NIfIZYZUSU6JRWK=
Ramos-2G6-4C10M4jmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLmdIxKSzVyPUO0MlI6QTNizszNNY\nVlhbW0GQR1XS
TE-11Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPFTWM2OD1|ND60PFIzKM7:TR?=MXPTRW5ITVJ?
L-428M3rtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHyS3ZuUUN3ME2zOE44PTN4IN88US=>MmLNV2FPT0WU
KP-N-YNMoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTN2LkmwOVch|ryPNWCweG05W0GQR1XS
CGTH-W-1NF7hdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jQN2lEPTB;M{[uPVA1QCEQvF2=MnrzV2FPT0WU
K-562NWXOUpFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmf1TWM2OD1|Nz6wPFY1KM7:TR?=NGXyRpNUSU6JRWK=
NCI-H1299MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFf0R5JKSzVyPUO4MlE3ODNizszNNHnMUmNUSU6JRWK=
RCC10RGBMnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjV[GRwUUN3ME2zPE4zODh|IN88US=>NH;HRlZUSU6JRWK=
NCI-SNU-16MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXodVFXUUN3ME2zPE42PjV|IN88US=>MlfWV2FPT0WU
LC-2-adNF;wcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\US5pjUUN3ME2zPU41OzN5IN88US=>MnftV2FPT0WU
MHH-PREB-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIW2NVNKSzVyPUO5Mlc{QDhizszNM3HZd3NCVkeHUh?=
NCI-H64MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLtZmMzUUN3ME20NE4xQTR6IN88US=>MUHTRW5ITVJ?
LB996-RCCMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PodWlEPTB;NECuPFcyPiEQvF2=M1\T[nNCVkeHUh?=
DELM1rDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzjZ4dsUUN3ME20NU41PDB3IN88US=>MWnTRW5ITVJ?
MLMAMnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnYeZFYUUN3ME20NU44PTl3IN88US=>NXywb5lbW0GQR1XS
SBC-1MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlflTWM2OD12Mj6xPFA3KM7:TR?=Mn7tV2FPT0WU
MPP-89M2PnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\4VWlEPTB;NEKuOVg4PSEQvF2=M2\xU3NCVkeHUh?=
MV-4-11M{G2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LBR2lEPTB;NEKuPVA3PyEQvF2=MoP2V2FPT0WU
EoL-1-M3O2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHIUpRKSzVyPUS0MlE2PjhizszNMVvTRW5ITVJ?
CW-2NUexW5gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvzTWM2OD12ND64N|QzKM7:TR?=MXHTRW5ITVJ?
HTMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHtUY4xUUN3ME20OU44ODB5IN88US=>NYezcIlbW0GQR1XS
SW954NXzHU5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LWOWlEPTB;NEeuOFEzQCEQvF2=MojTV2FPT0WU
A3-KAWNV;sSWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTR7LkiwOlEh|ryPM1XMUnNCVkeHUh?=
TC-YIKM2DT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTVyLkCzOlMh|ryPM2\PTXNCVkeHUh?=
SW962MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHTUolKSzVyPUW0Mlg{PTdizszNM{n0SnNCVkeHUh?=
KP-N-RT-BM-1NWK1bnY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTV4Lk[2N|gh|ryPM{P5bHNCVkeHUh?=
NCI-H1395NEfHZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknkTWM2OD13OD64NVczKM7:TR?=NU\WeJM3W0GQR1XS
RPMI-8402NF;JVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTV6Lkm1NlYh|ryPNF3aZo5USU6JRWK=
SCHMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TQcWlEPTB;NkCuPVY{QCEQvF2=NEXrT4VUSU6JRWK=
NCI-H2196NF;DUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnQXnRMUUN3ME22NU4zOzFizszNMnK4V2FPT0WU
LOXIMVIMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTZzLkiyOlYh|ryPMYHTRW5ITVJ?
TGBC24TKBMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmj4TWM2OD14Mj6xOFkyKM7:TR?=MnewV2FPT0WU
SK-MEL-2M{fJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jORmlEPTB;NkOuPVg6OiEQvF2=MnP4V2FPT0WU
U-698-MNES1S21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\tOGR1UUN3ME22PE42Pjh5IN88US=>NWDDdlhlW0GQR1XS
NCI-H1522M4rkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlW5TWM2OD14OT6wNFQ4KM7:TR?=MVPTRW5ITVJ?
UACC-812Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTLXm5KSzVyPU[5MlUzODlizszNMXzTRW5ITVJ?
MHH-CALL-2NFjXVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTyTWM2OD15MD6wOkDPxE1?M3z0O3NCVkeHUh?=
NB5MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTdyLkO0Olgh|ryPM3PFO3NCVkeHUh?=
KARPAS-299NIe0VlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7vTWM2OD15MD60OFQ4KM7:TR?=NULQ[XV2W0GQR1XS
NCI-H1694M2XTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrY[FhKSzVyPUexMlA{OiEQvF2=NG\tNI9USU6JRWK=
NCI-H82NX7RU5prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUH6d4NTUUN3ME23NU46PTB5IN88US=>NHXYNVdUSU6JRWK=
SCC-15MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTd{LkO0JO69VQ>?MXvTRW5ITVJ?
NCI-H1436MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVG3NIlKUUN3ME23Nk44PDV4IN88US=>MkPMV2FPT0WU
ATN-1NGG1SJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTd2LkWwOUDPxE1?M3rJdnNCVkeHUh?=
RPMI-8866NVH0OYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fBfGlEPTB;N{SuO|UxQSEQvF2=MnPvV2FPT0WU
HCC1599M1rLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTd2Lki3N|Ih|ryPMYTTRW5ITVJ?
NCI-H1155Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PBWGlEPTB;N{SuPVM3PyEQvF2=NY[1NpBIW0GQR1XS
DOHH-2NH7SWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjTVJVKSzVyPUe0Mlk2OTRizszNNXq1SHEzW0GQR1XS
SK-NEP-1M2Dl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\xTWM2OD15NT6wO|U1KM7:TR?=M3rRU3NCVkeHUh?=
HCC1187NV61S25VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{G2TmlEPTB;N{euOlEzOiEQvF2=MX7TRW5ITVJ?
NCI-H322MNXjEUotWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTd6LkO3NFkh|ryPNEnJVoJUSU6JRWK=
NCI-H526NXnZeWJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\VTWxKSzVyPUe4MlU5PzdizszNMn3CV2FPT0WU
NCI-H2171MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHnPXd{UUN3ME23PU41OTN4IN88US=>M3jxe3NCVkeHUh?=
COLO-668NYPKbnlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRThzLkW4PFQh|ryPMmT0V2FPT0WU
RS4-11MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHpdmVTUUN3ME24Nk4zPTB3IN88US=>MUjTRW5ITVJ?
NCI-H716MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknjTWM2OD16Mj65NFc2KM7:TR?=MYjTRW5ITVJ?
LU-134-ANHrsT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrkUIFOUUN3ME24N{4yOzVzIN88US=>M4DCdHNCVkeHUh?=
RPMI-8226M2TvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEf2bWxKSzVyPUi0MlIyODdizszNMWLTRW5ITVJ?
KY821NFL6R4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTlzLk[1OVEh|ryPMor1V2FPT0WU
ECC4Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;GUmlEPTB;OUOuPFI3QSEQvF2=MXrTRW5ITVJ?
EW-3M4LUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXiXIViUUN3ME25OE46ODhzIN88US=>NGjQbHZUSU6JRWK=
NB7NV2xWWpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDQXVdKSzVyPUm1Mlc4QDZizszNNGW0Z3JUSU6JRWK=
NCI-H720NV;jZYV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXVTWM2OD17OD60NFYyKM7:TR?=NIrL[YpUSU6JRWK=
NCI-H446Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7BfHNKSzVyPUm5Mlc2QDhizszNNGrLWmpUSU6JRWK=
NCI-H889M{nJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFyND6yOFIh|ryPMYDTRW5ITVJ?
EW-22MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTFyNj6xPUDPxE1?NH3xU|dUSU6JRWK=
BV-173NV65Tph1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTFyOD63Nlgh|ryPMl2zV2FPT0WU
WSU-NHLNIXOOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHuRYZKSzVyPUGwPU43PzFizszNMUHTRW5ITVJ?
MN-60NVWwXIxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTFyOT62PUDPxE1?MmrvV2FPT0WU
DG-75MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\ZV2NKSzVyPUGxN{4{PTJizszNNXLzcHdiW0GQR1XS
DMS-79M4\lPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmm3TWM2OD1zMUeuN|gzKM7:TR?=NIHwPIFUSU6JRWK=
SK-MEL-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2e0cGlEPTB;MUG4MlAxQSEQvF2=NVTZZW5kW0GQR1XS
DMS-153NEfQd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTF{MT63OFUh|ryPM1PXbHNCVkeHUh?=
NCI-H510AMkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jnV2lEPTB;MUK3MlMzKM7:TR?=MljIV2FPT0WU
BE-13M1rGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;TUlV3UUN3ME2xN|QvODR2IN88US=>NEPCN2lUSU6JRWK=
KP-N-YSM3Gw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPqdIdwUUN3ME2xN|kvPzN4IN88US=>MlfJV2FPT0WU
SUP-T1MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnT0TWM2OD1zNEOuO|A5KM7:TR?=MUnTRW5ITVJ?
EW-12NVXheG9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTF2ND62PVkh|ryPMXnTRW5ITVJ?
NB14M{C2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHsT4dzUUN3ME2xOFcvODh{IN88US=>NGm0dVFUSU6JRWK=
MDA-MB-134-VIMlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnmTWM2OD1zNEiuNlY5KM7:TR?=M3TONXNCVkeHUh?=
NCI-H1770M1XScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIq2WmRKSzVyPUG1Ok4zPzlizszNMnLJV2FPT0WU
TURMlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\jdoJKSzVyPUG2O{45PyEQvF2=MlLUV2FPT0WU
NCI-H1417M3X4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnjTWM2OD1zOECuN|MyKM7:TR?=NF\CUpNUSU6JRWK=
IMR-5NFfpb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljsTWM2OD1zOEGuOVcyKM7:TR?=M{XRU3NCVkeHUh?=
NCI-H226NWrKZWQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fvb2lEPTB;MUi4Mlg3PiEQvF2=NXSwT3ltW0GQR1XS
NCI-H187NGfh[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPITWM2OD1zOUCuNFY1KM7:TR?=NHL5d2xUSU6JRWK=
SF539M1jRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7mZ3J[UUN3ME2xPVIvPzJ6IN88US=>M1XMbXNCVkeHUh?=
TALL-1NHiwTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfaOnQzUUN3ME2xPVgvOzB2IN88US=>MVjTRW5ITVJ?
TE-441-TMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\Xc5p5UUN3ME2xPVkvPzN7IN88US=>MUfTRW5ITVJ?
REHM2PSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTJ|Nj62NlYh|ryPM1HSbHNCVkeHUh?=
MS-1MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfOW2lGUUN3ME2yN|kvOTJzIN88US=>MXXTRW5ITVJ?
THP-1MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj5[3FKSzVyPUK2OE44OzhizszNNVvpVotrW0GQR1XS
NCI-H1838MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;LV2lEPTB;MkexMlQ2PiEQvF2=NILEUGFUSU6JRWK=
P30-OHKMlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTJ6Mz64OFch|ryPMl;aV2FPT0WU
C8166MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjrTWM2OD1|NEWuN|M5KM7:TR?=MX7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us